Zur Rose Group AG successfully completes CHF 212 million capital increase

Frankfurt am Main, 17 July 2020. Zur Rose Group AG (the “Company” or “Zur Rose Group”) successfully completed the capital increase that was resolved yesterday. A total of 740,823 new shares were sold in an international private placement to institutional investors at a placement price of CHF 287.00 per new share (the “Placement Price”).

The share capital of the Company will increase from currently CHF 289,199,160 by CHF 22,224,690 to CHF 311,423,850 by issuing 740,823 registered shares each with a par value of CHF 30.00 (the “New Shares”) against cash contributions, making full use of the existing authorized share capital pursuant to section 3 a) of the Company’s articles of association (the “Capital Increase”). The New Shares carry full dividend rights for the fiscal year 2020 beginning on 1 January 2020.

The Capital Increase generates net proceeds of CHF 212.6 million which Zur Rose Group intends to use to fund an accelerated roll out of its e-prescription solutions (eRX) and European growth initiatives to broaden its customer base through organic expansion as well as potential acquisitions, to invest in platform and ecosystem partnerships and to fund the acquisition of TeleClinic), as well as for general corporate purposes.

The New Shares will be admitted to trading without prospectus on the International Reporting Standard segment of SIX Swiss Exchange immediately after the Capital Increase has been registered with the commercial register which is expected to take place on 20 July 2020. The first day of trading is expected to be 21 July 2020.

The Company has agreed to a 90-day lock-up period from the Settlement Date, subject to customary exceptions.

ACXIT Capital Partners acted as financial advisor to the Company.

Jefferies and BofA Securities acted as Joint Global Coordinators and Joint Bookrunners for the Capital Increase.

Baker McKenzie acted as legal counsel to Zur Rose Group.

About Zur Rose Group

The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany’s best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and has around seven million active customers in core European markets. (www.zurrosegroup.com)

About ACXIT

ACXIT Capital Partners is a leading international corporate finance and financial advisory firm for mid-market clients and entrepreneurs in Europe and beyond. Since 1998, we offer our clients comprehensive corporate finance advisory services including M&A and capital markets advisory as well as restructuring, debt and strategic advisory. As an independent, privately owned firm we maintain offices and representations in Frankfurt, Berlin, Munich, Zurich, Hong Kong and New York as well as strong alliances in UK, France and India.

Download the PDF of the English press release here.
Zum PDF-Download der deutschen Pressemitteilung klicken Sie bitte hier.

 

PRESS CONTACT

ACXIT Capital Holding GmbH
WestendDuo
Bockenheimer Landstraße 24
60323 Frankfurt am Main
Germany
www.acxit.com

facebook.com/acxitcapital
twitter.com/acxitcapital
xing.com/companies/acxitcapitalpartners
linkedin.com/company/acxit-capital-partners

Patric Garvin
Director, Strategic Communications

FTI Consulting
Park Tower | Bockenheimer Anlage 44
60322 Frankfurt am Main
Phone: +49 69 92037 125
Mobile: +49 151 4080 3312
E-mail: patric.garvin@fticonsulting.com

TRANSACTION LEAD ACXIT Capital Partners

Johannes H. Lucas, Managing Partner
Jens Tschauder, Managing Partner